Skip to main content
Erschienen in: Pediatric Nephrology 6/2014

01.06.2014 | Brief Report

N-acetyl-cysteine is associated to renal function improvement in patients with nephropathic cystinosis

verfasst von: Luciana Pache de Faria Guimaraes, Antonio Carlos Seguro, Maria Heloisa Mazzola Shimizu, Letícia Aparecida Lopes Neri, Nairo Massakasu Sumita, Ana Carolina de Bragança, Rildo Aparecido Volpini, Talita Rojas Cunha Sanches, Fernanda Andrade Macaferri da Fonseca, Carlos Alberto Moreira Filho, Maria Helena Vaisbich

Erschienen in: Pediatric Nephrology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Nephropathic cystinosis is an autosomal recessive systemic severe disease characterized by intralysosomal cystine storage. Cysteamine is an essential component of treatment. There is solid evidence that cystine accumulation itself is not responsible for all abnormalities in cystinosis; there is also a deficiency of glutathione in the cytosol. Patients with cystinosis can be more susceptible to oxidative stress.

Case-Diagnosis/Treatment

The patient cohort comprised 23 cystinosis patients (16 males) aged <18 years (mean age 8.0 ± 3.6 years) with chronic kidney disease class I–IV with good adherence to treatment, including cysteamine. Oxidative stress was evaluated based on the levels of serum thiobarbituric acid-reactive substances (TBARS), and renal function was evaluated based on serum creatinine and cystatin C levels and creatinine clearance (Schwartz formula). N-Acetylcysteine (NAC), an antioxidant drug was given to all patients for 3 months (T1) at 25 mg/kg/day divided in three doses per day. The measured values at just before the initiation of NAC treatment (T0) served as the control for each patient.

Results

Median serum TBARS levels at T0 and T1 were 6.92 (range 3.3–29.0) and 1.7 (0.6–7.2)  nmol/mL, respectively (p < 0.0001). In terms of renal function at T0 and T1, serum creatinine levels (1.1 ± 0.5 vs. 0.9 ± 0.5 mg/dL, respectively; p < 0.0001), creatinine clearance (69.7 ± 32.2 vs. T1 = 78.5 ± 33.9 mL/min/1.73 m2, respectively; p = 0.006), and cystatin c level (1.33 ± 0.53 vs. 1.15 ± 0.54 mg/l, respectively; p = 0.0057) were all significantly different at these two time points. Serum creatinine measurements at 6 (T −6) and 3 months (T −3) before NAC initiation and at 3 (T +3) and 6 months (T +6) after NAC had been withdrawn were also evaluated.

Conclusion

During the 3-month period that our 23 cystinosis patients were treated with NAC, oxidative stress was reduced and renal function significantly improved. No side-effects were detected. Larger and controlled studies are needed to confirm these findings.
Literatur
1.
Zurück zum Zitat Gahl WA, Tietze F, Bashan W (1982) Defective cystic exodus from isolated lysosome-rich fractions of cystinotic leukocytes. J Biol Hem 257(16):9570–9575 Gahl WA, Tietze F, Bashan W (1982) Defective cystic exodus from isolated lysosome-rich fractions of cystinotic leukocytes. J Biol Hem 257(16):9570–9575
2.
Zurück zum Zitat Town M, Jean G, Cherqui S, Attard M, Forestier L, Whitmore SA, Callen DF, Gribouval O, Broyer M, Bates GP, van't Hoff W, Antignac C (1998) A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nat Genet 18(4):319–324PubMedCrossRef Town M, Jean G, Cherqui S, Attard M, Forestier L, Whitmore SA, Callen DF, Gribouval O, Broyer M, Bates GP, van't Hoff W, Antignac C (1998) A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nat Genet 18(4):319–324PubMedCrossRef
3.
Zurück zum Zitat Vaisbich MH, Koch VH, The Brazilian Cystinosis Study Group (2010) Report of a Brazilian multicenter study on nephropathic cystinosis. Nephron Clin Pract 114:c12–c18PubMedCrossRef Vaisbich MH, Koch VH, The Brazilian Cystinosis Study Group (2010) Report of a Brazilian multicenter study on nephropathic cystinosis. Nephron Clin Pract 114:c12–c18PubMedCrossRef
4.
Zurück zum Zitat Brodin-Sartorius A, Tête MJ, Niaudet P, Antignac C, Guest G, Ottolenghi C, Charbit M, Moyse D, Legendre C, Lesavre P, Cochat P, Servais A (2012) Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int 81:179–189PubMedCrossRef Brodin-Sartorius A, Tête MJ, Niaudet P, Antignac C, Guest G, Ottolenghi C, Charbit M, Moyse D, Legendre C, Lesavre P, Cochat P, Servais A (2012) Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int 81:179–189PubMedCrossRef
5.
Zurück zum Zitat Gahl WA, Balog JZ, Kleta R (2007) Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy. Ann Int Med 147:242–250PubMedCrossRef Gahl WA, Balog JZ, Kleta R (2007) Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy. Ann Int Med 147:242–250PubMedCrossRef
6.
Zurück zum Zitat Greco M, Brugnara M, Zaffanello M, Taranta A, Pastore A, Emma F (2010) Long-term outcome of nephropathic cystinosis: a 20-year single-center experience. Pediatr Nephrol 25:2459–2467PubMedCrossRef Greco M, Brugnara M, Zaffanello M, Taranta A, Pastore A, Emma F (2010) Long-term outcome of nephropathic cystinosis: a 20-year single-center experience. Pediatr Nephrol 25:2459–2467PubMedCrossRef
7.
Zurück zum Zitat Wilmer MJ, de Graaf-Hess A, Blom HJ, Dijkman HB, Monnens LA, van den Heuvel LP, Levtchenko EN (2005) Elevated oxidized glutathione in cystinotic proximal tubular epithelial cells. Biochem Biophysl Res Commun 337:610–614CrossRef Wilmer MJ, de Graaf-Hess A, Blom HJ, Dijkman HB, Monnens LA, van den Heuvel LP, Levtchenko EN (2005) Elevated oxidized glutathione in cystinotic proximal tubular epithelial cells. Biochem Biophysl Res Commun 337:610–614CrossRef
8.
Zurück zum Zitat Sansanwal P, Yen B, Gahl WA, Ma Y, Ying L, Wong LJ, Sarwal MM (2010) Mitochondrial autophagy promotes cellular injury in nephropathic cystinosis. J Am Soc Nephrol 21:272–283PubMedCentralPubMedCrossRef Sansanwal P, Yen B, Gahl WA, Ma Y, Ying L, Wong LJ, Sarwal MM (2010) Mitochondrial autophagy promotes cellular injury in nephropathic cystinosis. J Am Soc Nephrol 21:272–283PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Wilmer MJ, Emma F, Levtchenko EN (2010) The pathogenesis of cystinosis: mechanisms beyond cystine accumulation. Am J Physiol Renal Physiol 299:F905–F916PubMedCrossRef Wilmer MJ, Emma F, Levtchenko EN (2010) The pathogenesis of cystinosis: mechanisms beyond cystine accumulation. Am J Physiol Renal Physiol 299:F905–F916PubMedCrossRef
10.
Zurück zum Zitat Levtchenko E, de Graaf-Hess A, Wilmer M, van den Heuvel L, Monnens L, Blom H (2005) Altered status of glutathione and its metabolites in cystinotic cells. Nephrol Dial Transplant 20:1828–1832PubMedCrossRef Levtchenko E, de Graaf-Hess A, Wilmer M, van den Heuvel L, Monnens L, Blom H (2005) Altered status of glutathione and its metabolites in cystinotic cells. Nephrol Dial Transplant 20:1828–1832PubMedCrossRef
11.
Zurück zum Zitat Vitvitsky V, Witcher M, Banerjee R, Thoene J (2010) The redox status of cystinotic fibroblasts. Mol Genet Metabol 99:384–388CrossRef Vitvitsky V, Witcher M, Banerjee R, Thoene J (2010) The redox status of cystinotic fibroblasts. Mol Genet Metabol 99:384–388CrossRef
13.
Zurück zum Zitat Hanly LN, Chen N, Aleksa K, Cutler M, Bajcetic M, Palassery R, Regueira O, Turner C, Baw B, Malkin B, Freeman D, Rieder MJ, Vasylyeva TL, Koren G (2012) N-acetylcysteine as a novel prophylactic treatment for ifosfamide-induced nephrotoxicity in children: translational pharmacokinetics. J Clin Pharmacol 52(1):55–64PubMedCrossRef Hanly LN, Chen N, Aleksa K, Cutler M, Bajcetic M, Palassery R, Regueira O, Turner C, Baw B, Malkin B, Freeman D, Rieder MJ, Vasylyeva TL, Koren G (2012) N-acetylcysteine as a novel prophylactic treatment for ifosfamide-induced nephrotoxicity in children: translational pharmacokinetics. J Clin Pharmacol 52(1):55–64PubMedCrossRef
14.
Zurück zum Zitat Duru M, Nacar A, Yönden Z, Kuvandik G, Helvaci MR, Koç A, Akaydin Y, Oksüz H, Söğüt S (2008) Protective effects of N-acetylcysteine on cyclosporine-A-induced nephrotoxicity. Ren Fail 30:453–459PubMedCrossRef Duru M, Nacar A, Yönden Z, Kuvandik G, Helvaci MR, Koç A, Akaydin Y, Oksüz H, Söğüt S (2008) Protective effects of N-acetylcysteine on cyclosporine-A-induced nephrotoxicity. Ren Fail 30:453–459PubMedCrossRef
15.
Zurück zum Zitat Luo J, Tsuji T, Yasuda H, Sun Y, Fujigaki Y, Hishida A (2008) The molecular mechanisms of the attenuation of cisplatin-induced acute renal failure by N-acetylcysteine in rats. Nephrol Dial Transplant 23:2198–2205PubMedCrossRef Luo J, Tsuji T, Yasuda H, Sun Y, Fujigaki Y, Hishida A (2008) The molecular mechanisms of the attenuation of cisplatin-induced acute renal failure by N-acetylcysteine in rats. Nephrol Dial Transplant 23:2198–2205PubMedCrossRef
16.
Zurück zum Zitat Drager LF, Andrade L, Toledo JFB, Laurindo FRM, Cesar LAM, Seguro AC (2004) Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant 19:1803–1807PubMedCrossRef Drager LF, Andrade L, Toledo JFB, Laurindo FRM, Cesar LAM, Seguro AC (2004) Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant 19:1803–1807PubMedCrossRef
17.
Zurück zum Zitat Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, Balk E, Lau J, Levin A, Kausz AT, Eknoyan G, Levey AS (2003) National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 111:1416–1421PubMedCrossRef Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, Balk E, Lau J, Levin A, Kausz AT, Eknoyan G, Levey AS (2003) National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 111:1416–1421PubMedCrossRef
18.
Zurück zum Zitat Schwartz GJ, Work DF (2009) Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 4:1832–1843PubMedCrossRef Schwartz GJ, Work DF (2009) Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 4:1832–1843PubMedCrossRef
19.
Zurück zum Zitat Shimizu MHM, Coimbra TM, Araujo M, Menezes LF, Seguro AC (2005) N-acetylcysteine attenuates the progression of chronic renal failure. Kidney Int 68:2208–2217PubMedCrossRef Shimizu MHM, Coimbra TM, Araujo M, Menezes LF, Seguro AC (2005) N-acetylcysteine attenuates the progression of chronic renal failure. Kidney Int 68:2208–2217PubMedCrossRef
20.
Zurück zum Zitat Danilovic A, Lucon AM, Srougi M, Shimizu MH, Ianhez LE, Nahas WC, Seguro AC (2011) Protective effect of N-acetylcysteine on early outcomes of deceased renal transplantation. Transplant Proc 43(5):1443–1449PubMedCrossRef Danilovic A, Lucon AM, Srougi M, Shimizu MH, Ianhez LE, Nahas WC, Seguro AC (2011) Protective effect of N-acetylcysteine on early outcomes of deceased renal transplantation. Transplant Proc 43(5):1443–1449PubMedCrossRef
21.
Zurück zum Zitat Dohil R, Fidler M, Gangoiti JA, Kaskel F, Schneider JA, Barshop BA (2010) Twice-daily cysteamine bitartrate therapy for children with cystinosis. J Pediatr 156(1):71–75, e3PubMedCrossRef Dohil R, Fidler M, Gangoiti JA, Kaskel F, Schneider JA, Barshop BA (2010) Twice-daily cysteamine bitartrate therapy for children with cystinosis. J Pediatr 156(1):71–75, e3PubMedCrossRef
22.
Zurück zum Zitat Yeagy BA, Harrison F, Gubler MC, Koziol JA, Salomon DR, Cherqui S (2011) Kidney preservation by bone marrow cell transplantation in hereditary nephropathy. Kidney Int 79(11):1198–1206PubMedCrossRef Yeagy BA, Harrison F, Gubler MC, Koziol JA, Salomon DR, Cherqui S (2011) Kidney preservation by bone marrow cell transplantation in hereditary nephropathy. Kidney Int 79(11):1198–1206PubMedCrossRef
23.
Zurück zum Zitat Wilmer MJ, Kluijtmans LA, van der Velden TJ, Willems PH, Scheffer PG, Masereeuw R, Monnens LA, van den Heuvel LP, Levtchenko EN (2011) Cysteamine restores glutathione redox status in cultured cystinotic proximal tubular epithelial cells. Biochim Biophys Acta 1812:643–651PubMedCrossRef Wilmer MJ, Kluijtmans LA, van der Velden TJ, Willems PH, Scheffer PG, Masereeuw R, Monnens LA, van den Heuvel LP, Levtchenko EN (2011) Cysteamine restores glutathione redox status in cultured cystinotic proximal tubular epithelial cells. Biochim Biophys Acta 1812:643–651PubMedCrossRef
24.
Zurück zum Zitat Aruoma OI, Halliwell B, Hoey BM (1989) The antioxidant action of N-acetylcysteine: its action with hydrogen peroxide, hydroxyl radical, superoxide and hipochlorous acid. Free Radic Biol Med 6:593PubMedCrossRef Aruoma OI, Halliwell B, Hoey BM (1989) The antioxidant action of N-acetylcysteine: its action with hydrogen peroxide, hydroxyl radical, superoxide and hipochlorous acid. Free Radic Biol Med 6:593PubMedCrossRef
25.
Zurück zum Zitat Ruiz Fuentes MC, Moreno Ayuso JM, Ruiz Fuentes N, Vargas Palomares JF, Asensio Peinado C, Osuna Ortega A (2008) Treatment with N-acetylcysteine in stable renal transplantation. Transplant Proc 40:2897–2899PubMedCrossRef Ruiz Fuentes MC, Moreno Ayuso JM, Ruiz Fuentes N, Vargas Palomares JF, Asensio Peinado C, Osuna Ortega A (2008) Treatment with N-acetylcysteine in stable renal transplantation. Transplant Proc 40:2897–2899PubMedCrossRef
26.
Zurück zum Zitat Guimarães LPF, Neri LAL, Sumita NM, Vaisbich MH (2011) Practical markers of renal function among patients with cystinosis. J Bras Nefrol 33(3):1–4 Guimarães LPF, Neri LAL, Sumita NM, Vaisbich MH (2011) Practical markers of renal function among patients with cystinosis. J Bras Nefrol 33(3):1–4
Metadaten
Titel
N-acetyl-cysteine is associated to renal function improvement in patients with nephropathic cystinosis
verfasst von
Luciana Pache de Faria Guimaraes
Antonio Carlos Seguro
Maria Heloisa Mazzola Shimizu
Letícia Aparecida Lopes Neri
Nairo Massakasu Sumita
Ana Carolina de Bragança
Rildo Aparecido Volpini
Talita Rojas Cunha Sanches
Fernanda Andrade Macaferri da Fonseca
Carlos Alberto Moreira Filho
Maria Helena Vaisbich
Publikationsdatum
01.06.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 6/2014
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-013-2705-3

Weitere Artikel der Ausgabe 6/2014

Pediatric Nephrology 6/2014 Zur Ausgabe

Educational Review

Uric acid and the kidney

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

22.04.2024 Fehlsichtigkeit Nachrichten

Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 Spinale Muskelatrophien Nachrichten

Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.